Accretion Pharmaceuticals Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹201 Cr

The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue. Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.

From Accretion Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹202

Market Cap

₹201 Cr

P/E Ratio

20.8

How does Accretion Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Accretion Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 1Margin: Rank 2

View Pharmaceuticals & Biotechnology leaderboard →

📊 Revenue & Sales Performance

Rank 1

→The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue.
→Management indicated optimism for continued rapid sales growth in upcoming years, supported by a healthy order book and expanding export markets.
→They anticipate leveraging newly added production capacity (with around a 40% capacity increase post-IPO), along with improved utilization and product mix, to drive volume growth.
→FY '26 revenue is expected to surpass last year's INR57 crores significantly, aiming around INR120-130 crores based on current momentum.
→The company plans to expand product registrations in new geographies (e.g., Rwanda, Nigeria, Cambodia) to bolster sales channels.
→Growth is supported by strategic bulk sourcing, supply diversification, efficiency gains, and tighter working capital management.
→While exact figures are not confirmed, management is confident in sustaining or improving existing growth rates going forward.

📈 Profitability & Margins

Rank 2

→Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth.
→The company anticipates EBITDA margins to improve from the current ~17% toward a steady-state of 20%-22%, as registration and scaling expenses normalize.
→Profit after tax (PAT) is projected to grow significantly; with confidence expressed in maintaining or exceeding current profit levels (e.g., PAT closer to INR 10 crores anticipated).
→Improved capacity utilization and expanded product registrations in multiple countries (e.g., Rwanda, Nigeria, Cambodia) will drive revenue and margin expansion.
→Operational efficiencies, bulk sourcing, supply diversification, and tighter working capital management are expected to enhance profitability.
→Long-term focus is on sustainable, profitable growth, value creation, and increasing return ratios supported by a healthy order book and strengthened balance sheet.

See what Accretion Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

Yes

→The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.
→The capex includes upgrading manufacturing facilities with new equipment to enhance capacity and compliance.
→Future capex plans involve continued expansion and equipment upgradation to strengthen CDMO capabilities.
→Focus on expanding product registrations and regulatory approvals in markets like Rwanda, Nigeria, Cambodia, and others to support growth.
→Working capital has been augmented to support growing orders and ensure operational agility.
→The company aims to sustain double-digit growth with a balanced mix of domestic and export revenues backed by these investments.
→Loan repayments have reduced debt, maintaining a healthy capital structure with adequate liquidity for future expansions.

💰 Fundraising & Capital Structure

No information

→The company has recently completed a successful IPO in May 2025, raising INR29.75 crores.
→Proceeds from the IPO have been strategically utilized for manufacturing facility upgrades, debt repayment, and working capital augmentation.
→Short-term and long-term borrowings have drastically reduced due to loan repayments post-IPO.
→There is no mention of any immediate or planned new fundraising through debt or equity in the call.
→The company emphasizes maintaining a healthy capital structure with low debt-to-equity ratio and adequate liquidity for future expansion.
→Focus remains on profitable growth, working capital efficiency, and prudent capital management without indicating any additional fundraising efforts currently.

See what Accretion Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

Yes

→The company currently has a good order book, which supports their confidence in maintaining momentum in upcoming quarters.
→They expect to sustain the growth rate seen in the first half of the year through efficient utilization of working capital and enhanced capacity.
→New product launches and expansion into new countries also contribute to anticipated revenue growth from the order book.
→The management confirms clarity on the existing order book and expects to deliver on these orders, contributing to PAT projections close to INR 10 crores for the year.
→Although specific numbers are not disclosed, the company expresses confidence based on established products and customer relationships.

Key Metrics

3 of 5 growth signals positive in the Q2 FY26 call.

Revenue

Rank 1

Margin

Rank 2

Capex

Yes

Fundraise

No information

Order Book

Yes

How does Accretion Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Accretion Pharmaceuticals Ltd

Rev 1Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Others in Pharmaceuticals & Biotechnology this season

ALIVUS (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
SUNPHARMA (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
ZYDUSLIFE (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Accretion Pharmaceuticals Ltd Q2 FY26 results?

What is Accretion Pharmaceuticals Ltd share price analysis?

Accretion Pharmaceuticals Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 20.8 with a market cap of ₹201 Cr. Investors should review the full earnings analysis for detailed insights.

Is Accretion Pharmaceuticals Ltd planning capital expenditure?

The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO.

Keep Accretion Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.